Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, and chronic diseases, announced that Dr. Richard Law has ...

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased ...

Eli Lilly (LLY) plans to spend at least $27 billion to build four ... Trump has taken aim at South Korea, saying its tariffs ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Lotte Biologics announced on the 13th that it has signed a memorandum of understanding (MOU) for collaboration in the ...